How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

594 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Androgenetic Alopecia. Modelling Progression and regrowth. (PubMed)

Androgenetic Alopecia. Modelling Progression and regrowth. 27061176 2018 01 31 2018 01 31 1600-0625 25 6 2016 06 Experimental dermatology Exp. Dermatol. Androgenetic alopecia. Modelling progression and regrowth. 424-5 10.1111/exd.13029 Sinclair Rodney R Department of Dermatology, University of Melbourne, Epworth Hospital, Melbourne, Vic., Australia. eng Journal Article Comment Denmark Exp Dermatol 9301549 0906-6705 IM Exp Dermatol. 2016 Jun;25(6):482-4 26782302 Alopecia Disease Progression Hair (...) Hair Follicle Humans androgenic balding female pattern baldness male 2016 03 29 2016 4 11 6 0 2016 4 12 6 0 2018 2 1 6 0 ppublish 27061176 10.1111/exd.13029

Full Text available with Trip Pro

2016 Experimental Dermatology

82. Study on Androgen Receptor and Triple Negative Breast Cancer

Study on Androgen Receptor and Triple Negative Breast Cancer Study on Androgen Receptor and Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study on Androgen Receptor (...) Information provided by (Responsible Party): UNICANCER Study Details Study Description Go to Brief Summary: This is a multicenter uncontrolled, open-label, prospective, non-comparative randomized, phase II study. Patients will be randomized between darolutamide in Arm n°1 (two-stage Simon's design) and capecitabine in Arm n°2 with two patients randomized in Arm n°1 for one patient randomized in Arm n°2. The trial population is composed of women over 18 years old with triple-negative and androgen receptor

2017 Clinical Trials

83. Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

2017 Clinical Trials

84. Androgens trigger different growth responses in genetically identical human hair follicles in organ culture that reflect their epigenetic diversity in life (PubMed)

: some remain unaffected ( e.g., eyelashes) or are inhibited, causing balding. How sex steroid hormones alter such developmental processes is unclear, despite high incidences of hormone-driven cancer, hirsutism, and alopecia. Unfortunately, existing development models are not androgen sensitive. Here, we use hair follicles to establish an androgen-responsive human organ culture model. We show that women's intermediate facial follicles respond to men's higher androgen levels by synthesizing more hair (...) Androgens trigger different growth responses in genetically identical human hair follicles in organ culture that reflect their epigenetic diversity in life Male sex hormones-androgens-regulate male physique development. Without androgen signaling, genetic males appear female. During puberty, increasing androgens harness the hair follicle's unique regenerative ability to replace many tiny vellus hairs with larger, darker terminal hairs ( e.g., beard). Follicle response is epigenetically varied

Full Text available with Trip Pro

2017 The FASEB Journal

85. Hair follicle stem cell differentiation is inhibited through a cross talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. (PubMed)

Hair follicle stem cell differentiation is inhibited through a cross talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Hair follicle (HF) regeneration begins when signals from the mesenchyme-derived dermal papilla cells (DPC) reach multipotent epidermal stem cells in the bulge region. Wnt/β-catenin signalling is known to affect mammalian hair growth positively. In androgenetic alopecia (AGA), androgens cause HF miniaturization (...) through a mechanism that remains unclear. Circulating androgens act on DPC and alter paracrine factors that influence hair epithelial cells.To elucidate the role of androgens in dermal papilla-induced differentiation of HF stem cells.HF stem cell differentiation was evaluated in a coculture model with DPC or culturing with media conditioned by DPC after activation of androgen and Wnt/β-catenin signalling pathways. To study the molecular cross-talk between the androgen and Wnt signalling pathway in DPC

2012 British Journal of Dermatology

86. Androgen receptor gene polymorphisms and risk for androgenetic alopecia: a meta-analysis. (PubMed)

Androgen receptor gene polymorphisms and risk for androgenetic alopecia: a meta-analysis. Numerous studies have shown an association between polymorphisms in the androgen receptor gene (AR) and the risk for androgenetic alopecia (AGA), but the overall results are still controversial.To determine, by conducting a meta-analysis, whether the common AR gene polymorphisms confer susceptibility to AGA.Publications addressing the association between AR gene polymorphisms and risk for AGA were selected

2012 Clinical and experimental dermatology

87. Androgenic Alopecia

Androgenic Alopecia Androgenic Alopecia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Androgenic Alopecia Androgenic Alopecia Aka (...) : Androgenic Alopecia , Androgenetic Alopecia , Male-patterned Baldness From Related Chapters II. Definition Non-scarring androgen related III. Epidemiology Most common type of (esp. white men) Hereditary trait (positive ) Increasing with age Affects white men 30% at age 30, 40% at age 40, 50% at age 50 years Affects 38% of women over age 70 years IV. Course onset between ages 12 to 40 years evident by age 50 in >50% of patients V. Pathophysiology Androgen exposure shortens phase Men with increased

2015 FP Notebook

88. Genome-wide gene expression dataset used to identify potential therapeutic targets in androgenetic alopecia (PubMed)

Genome-wide gene expression dataset used to identify potential therapeutic targets in androgenetic alopecia The microarray dataset attached to this report is related to the research article with the title: "A genomic approach to susceptibility and pathogenesis leads to identifying potential novel therapeutic targets in androgenetic alopecia" (Dey-Rao and Sinha, 2017) [1]. Male-pattern hair loss that is induced by androgens (testosterone) in genetically predisposed individuals is known (...) as androgenetic alopecia (AGA). The raw dataset is being made publicly available to enable critical and/or extended analyses. Our related research paper utilizes the attached raw dataset, for genome-wide gene-expression associated investigations. Combined with several in silico bioinformatics-based analyses we were able to delineate five strategic molecular elements as potential novel targets towards future AGA-therapy.

Full Text available with Trip Pro

2017 Data in brief

89. Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation of Hypothalamic-Pituitary-Adrenal Axis? (PubMed)

Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation of Hypothalamic-Pituitary-Adrenal Axis? 21769240 2011 11 10 2018 11 13 0974-9241 3 1 2011 Jan International journal of trichology Int J Trichology Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation

Full Text available with Trip Pro

2011 International journal of trichology

90. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. (PubMed)

Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. When studies of postmenopausal women with hair loss failed to reveal a response to the 5 alpha reductase inhibitor, finasteride, researchers began to question the existence of androgenetic alopecia in women and renamed the clinical entity female pattern hair loss. However, recently published reports of finasteride response in some women (...) with hair loss suggest that an androgenic mechanism is mediating response in this group. Variant repeat nucleotide sequences in exon 1 of the androgen receptor (AR) gene have been shown to determine androgen sensitivity in a variety of androgenic conditions in men and women. In an effort to identify whether this AR variant may help determine which women are likely to respond to finasteride therapy, a pilot study was undertaken. In our 6-month pilot of 13 patients, women with greater androgen sensitivity

2011 Dermatologic therapy

91. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. (PubMed)

Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. Androgenetic alopecia (AGA) is characterized by vellus transformation of scalp hairs, corresponding to hair follicle miniaturization during repeated hair cycles with shortened anagen phase. This phenomenon is mediated mainly by androgen. Then, the multi-step molecular pathway of androgen can be involved in the pathogenesis of AGA. The expression of type II 5α-reductase is higher in dermal (...) papilla cells from AGA and beard than those from other sites. On the other hand, type I 5α-reductase expression is relatively low. Next, hormone binding assays and RT-PCR demonstrated that androgen receptor (AR) expression is significantly higher in bald dermal papilla cells than non-bald cells. Additionally, AR coactivator Hic-5/ARA55 is highly expressed in dermal papilla cells of hair follicles from androgen-sensitive sites such as AGA and beard. Collectively, the enhanced expression of type II 5α

2011 Journal of dermatological science

92. Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01325337 Recruitment Status : Completed First Posted : March 29, 2011 Results First Posted : April 10, 2014 Last Update Posted : April 10

2011 Clinical Trials

93. Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

) and HER2 negative breast cancer by IHC and /or fluorescence in situ hybridization (FISH) Androgen receptor positive (AR+) Defined as >= 50% nuclear AR staining by immunohistochemistry (IHC) in either the primary or metastatic lesion NOTE: Research testing of AR status is available at City of Hope Pathology Resolution of grade 2 and above toxicities of most recent therapy except for stable sensory neuropathy (=< grade 2) and alopecia Female (childbearing potential): use an adequate method of birth (...) Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2016 Clinical Trials

94. Androgen excess: Investigations and management. (PubMed)

Androgen excess: Investigations and management. Androgen excess (AE) is a key feature of polycystic ovary syndrome (PCOS) and results in, or contributes to, the clinical phenotype of these patients. Although AE will contribute to the ovulatory and menstrual dysfunction of these patients, the most recognizable sign of AE includes hirsutism, acne, and androgenic alopecia or female pattern hair loss (FPHL). Evaluation includes not only scoring facial and body terminal hair growth using (...) the modified Ferriman-Gallwey method but also recording and possibly scoring acne and alopecia. Moreover, assessment of biochemical hyperandrogenism is necessary, particularly in patients with unclear or absent hirsutism, and will include assessing total and free testosterone (T), and possibly dehydroepiandrosterone sulfate (DHEAS) and androstenedione, although these latter contribute limitedly to the diagnosis. Assessment of T requires use of the highest quality assays available, generally

2016 Best practice & research. Clinical obstetrics & gynaecology

95. LEO 124249 Ointment in the Treatment of Alopecia Areata

) investigator, affecting a minimum of 30% scalp area at Visit 1 (Screening) and Visit 2 (Day 1, baseline). Minimum 6 month duration of hair loss at Visit 1 (Screening). No upper limit time limit. Subject must accept to not cut hair in the treated scalp areas during the trial. Exclusion Criteria: Females who are pregnant or are breast feeding. Current signs of spontaneous hair regrowth. Diffuse type alopecia areata. Co-existing moderate to severe androgenic alopecia (Norwood-Hamilton stage IV-VI and Ludwig (...) LEO 124249 Ointment in the Treatment of Alopecia Areata LEO 124249 Ointment in the Treatment of Alopecia Areata - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. LEO 124249 Ointment in the Treatment

2015 Clinical Trials

96. Adipose-derived SVF for Treatment of Alopecia

subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia. Device: GID SVF-2 Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth. Outcome Measures Go to Primary Outcome Measures : Incidence of Treatment-emergent Adverse Events (Safety) [ Time (...) Adipose-derived SVF for Treatment of Alopecia Adipose-derived SVF for Treatment of Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adipose-derived SVF for Treatment of Alopecia The safety

2015 Clinical Trials

97. All about hair loss (alopecia) - Deutsche Welle expert interview

Treatments: Drugs Minoxidil shampoo Patients can buy an OTC shampoo with an ingredient called minoxidil. Minoxidil (Rogaine) fights androgenic alopecia in both men and women. It's still not entirely clear how minoxidil works. Used properly -- twice a day, massaged deep into the scalp -- it slows new hair loss. Two-thirds of men do get acceptable hair growth. "It is not something a bald person would use, but someone starting to go bald would use it. The goal is to maintain the hair you have." An example (...) All about hair loss (alopecia) - Deutsche Welle expert interview CasesBlog - Medical and Health Blog: All about hair loss (alopecia) - Deutsche Welle expert interview Health News Updated Daily by Internist and Allergist at Cleveland Clinic Florida Pages All about hair loss (alopecia) - Deutsche Welle expert interview Dr. Andreas Finner (Trichomed Praxis Berlin) talks about what everyone can do to keep a full head of hair and about the best methods for treating hair loss: Today's Hair-Loss

2015 CasesBlog - Medical and Health Blog

98. STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

: Other Study ID Numbers: 003-A-II First Posted: July 21, 2015 Last Update Posted: March 7, 2018 Last Verified: March 2018 Keywords provided by Kerastem Technologies, LLC: Female Pattern Baldness Male Pattern Baldness Genetic Alopecia Androgenic Alopecia Hair Loss Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical (...) STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. STYLE -- A Trial

2015 Clinical Trials

99. A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our

2015 Clinical Trials

100. Conditions simulating androgenetic alopecia. (PubMed)

Conditions simulating androgenetic alopecia. Androgenetic alopecia is a common form of hair loss, characterized by a progressive hair follicular miniaturization, caused by androgen hormones on a genetically susceptible hair follicle, in androgenic-dependent areas. Characteristic phenotype of androgenetic alopecia is also observed in many other hair disorders. These disorders are androgenetic-like diseases that cause many differential diagnosis or therapeutic error problems. The objective

Full Text available with Trip Pro

2015 Journal of the European Academy of Dermatology and Venereology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>